Invasive Pneumococcal Disease

The FDA has accepted for priority review a supplemental biologics license application for Pfizer’s 20-valent pneumococcal conjugate vaccine for use in infants and children aged 6 weeks to 17 years, Pfizer announced.

Merck’s investigational V114 pneumococcal conjugate vaccine, which includes 15 serotypes, met its primary immunogenicity and safety endpoints in two phase 3 pediatric trials, the company announced.